T. Yanagawa, Hideomi Watanabe, T. Shinozaki, K. Takagishi
{"title":"FDG PET在原发性骨肿瘤中的应用2009-05-15 2009-12-18 2010-03-25","authors":"T. Yanagawa, Hideomi Watanabe, T. Shinozaki, K. Takagishi","doi":"10.2174/1876525401002010019","DOIUrl":null,"url":null,"abstract":"Positron emission tomography (PET) using ( 18 F)fluorodeoxyglucose (FDG) is a useful modality to examine many kinds of tumors, including primary bone tumors. Malignant bone tumors show higher FDG accumulation than benign tumors and earlier reports mention that FDG-PET can differentiate malignancy from benignancy; however, some benign bone tumors present with high FDG accumulation, which increases false positive rates in FDG-PET. FDG accumulation reflects glucose metabolism and thereby FDG-PET can be used for staging malignant bone tumors, which require a large amount of glucose. Combined with conventional studies, such as magnetic resonance imaging (MRI) and scintigraphy, FDG-PET can more accurately decide the staging. Finally, FDG-PET is also applied to evaluate the chemotherapy response of malignant bone tumors and is expected to predict a patient's prognosis and to help to decide appropriate chemotherapy agents.","PeriodicalId":89634,"journal":{"name":"The Open bone journal","volume":"2 1","pages":"19-23"},"PeriodicalIF":0.0000,"publicationDate":"2010-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Usefulness of FDG PET in Primary Bone Tumors~!2009-05-15~!2009-12-18~!2010-03-25~!\",\"authors\":\"T. Yanagawa, Hideomi Watanabe, T. Shinozaki, K. Takagishi\",\"doi\":\"10.2174/1876525401002010019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Positron emission tomography (PET) using ( 18 F)fluorodeoxyglucose (FDG) is a useful modality to examine many kinds of tumors, including primary bone tumors. Malignant bone tumors show higher FDG accumulation than benign tumors and earlier reports mention that FDG-PET can differentiate malignancy from benignancy; however, some benign bone tumors present with high FDG accumulation, which increases false positive rates in FDG-PET. FDG accumulation reflects glucose metabolism and thereby FDG-PET can be used for staging malignant bone tumors, which require a large amount of glucose. Combined with conventional studies, such as magnetic resonance imaging (MRI) and scintigraphy, FDG-PET can more accurately decide the staging. Finally, FDG-PET is also applied to evaluate the chemotherapy response of malignant bone tumors and is expected to predict a patient's prognosis and to help to decide appropriate chemotherapy agents.\",\"PeriodicalId\":89634,\"journal\":{\"name\":\"The Open bone journal\",\"volume\":\"2 1\",\"pages\":\"19-23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open bone journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1876525401002010019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open bone journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876525401002010019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Usefulness of FDG PET in Primary Bone Tumors~!2009-05-15~!2009-12-18~!2010-03-25~!
Positron emission tomography (PET) using ( 18 F)fluorodeoxyglucose (FDG) is a useful modality to examine many kinds of tumors, including primary bone tumors. Malignant bone tumors show higher FDG accumulation than benign tumors and earlier reports mention that FDG-PET can differentiate malignancy from benignancy; however, some benign bone tumors present with high FDG accumulation, which increases false positive rates in FDG-PET. FDG accumulation reflects glucose metabolism and thereby FDG-PET can be used for staging malignant bone tumors, which require a large amount of glucose. Combined with conventional studies, such as magnetic resonance imaging (MRI) and scintigraphy, FDG-PET can more accurately decide the staging. Finally, FDG-PET is also applied to evaluate the chemotherapy response of malignant bone tumors and is expected to predict a patient's prognosis and to help to decide appropriate chemotherapy agents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
